Technology News

  • EpiSonica Gains Regulatory Approval in Taiwan

    Taiwan-based EpiSonica has secured Taiwan Food & Drug Administration (TFDA) clearance of its ArcBlate MR-guided focused ultrasound system for soft tumor ablation of uterine fibroids, adenomyosis, and palliative pain care. ArcBlate can be used in any commercial MRI system.

    Continue reading >

  • GBM Consortium Tests Focused Ultrasound Immunomodulation Parameters

    The Foundation’s multi-site consortium to streamline efforts and accelerate progress in using FUS to increase the body’s anti-tumor immune response has launched its first major project. Researchers at seven institutions will investigate the effects of different FUS modalities on the immune system, each using the same animal model of glioblastoma multiforme (GBM), an aggressive and difficult to treat brain tumor.

    Continue reading >

  • FUS Immunotherapy Summit Builds on Momentum

    More than 40 experts from around the world gathered for the Focused Ultrasound and Immunotherapy Summit, held in partnership with the Cancer Research Institute on October 14. The group met to critically evaluate the current body of evidence, assess the value of ongoing work, and create a roadmap of projects to address any remaining gaps or questions.

    Continue reading >

  • Symposium Summary & Presentation Videos Now Available

    Nearly 200 researchers presented their data at the 5th International Symposium on Focused Ultrasound in August. The Symposium is the world's leading forum for sharing the latest translational and clinical advances in focused ultrasound – a groundbreaking non-invasive therapeutic technology. Targeted to scientists, clinicians, and other stakeholders, the conference offered a multifaceted exploration of this emerging field and feature plenary sessions, panel discussions, poster presentations and technical exhibits.

    Read the event summary. 

    You can now view the video presentations and read the abstracts here.

     

    symposium 2016 art module 150

     

     

    Continue reading >

  • Physicists in Medicine Meeting Report

    Kullervo Hynynen, PhD, Professor of Medical Biophysics at the University of Toronto presented a distinguished lecture at the American Association of Physicists in Medicine (AAPM) Annual Meeting. The lecture, entitled “Advances in Ultrasound Therapy,” explained the principles, technology, and techniques behind focused ultrasound and its clinical use for drug delivery.

    Continue reading >

  • FUS and the Cancer Moonshot

    Also: Blue Ribbon Panel Issues Recommendations

    four pillars module newThrough its eventual integration into the four pillars of traditional cancer treatment, focused ultrasound has the potential to transform the treatment of cancer.

    In a feature published on the social journalism website Medium.com, Chief Scientific Officer, Jessica Foley, PhD, and Foundation Chairman Neal F. Kassell, MD, write about how focused ultrasound can enhance or replace surgery, radiation therapy, chemotherapy, and immunotherapy for cancer.

    Continue reading >

  • News Flash - First Epilepsy Trial

     

    World's First Focused Ultrasound Clinical Trial for Epilepsy Begins
    Researchers at the University of Virginia (UVA) are starting the first clinical trial in the world using focused ultrasound to treat patients with epilepsy. The study, supported by the Focused Ultrasound Foundation in collaboration with the Epilepsy Foundation, will assess the feasibility, safety and initial effectiveness of focused ultrasound to non-invasively destroy (ablate) diseased brain tissue that causes seizures.
    The study is now recruiting up to 15 adult patients with a range of rare deep brain lesions that produce debilitating seizures that often do not respond to medications.  It is expected that most patients in the study will have benign tumors in the hypothalamus, which can lead to frequent seizures with outbursts of spontaneous laughing, giggling, crying or grunting; developmental delays and/or precocious puberty. The disorder can progress as patients age, leading to increased cognitive decline and severe behavior problems.
    Current options for patients whose seizures do not respond to medication include surgery or laser thermal ablation, both which may involve multiple risks or complications, such as damage to normal brain, infection or hemorrhage.  The only currently available non-invasive method is radiosurgery with the gamma knife, which may take months to show effect, is not image guided and involves risks of complications from radiation.
    “Intractable epilepsy, especially this type, can be devastating and existing therapies have risks and are not uniformly effective, so many patients are in desperate need of better therapies,” says principal investigator Nathan Fountain, MD, professor of neurology at UVA. “If we are successful in destroying the lesions without complications, then this will be an important step on the path toward developing focused ultrasound to enable patients to have freedom from seizures without the risks of open surgery.”
    Dr. Fountain will collaborate with UVA neurosurgeon Jeff Elias, MD, in conducting the procedures using Insightec’s Exablate Neuro System. Patients seeking further information about the study should contact Stacy Thompson, RN at or Nathan Fountain, MD at .
    Momentum Building for FUS and Epilepsy

    “We are committed to advancing the technical, scientific and clinical work required for focused ultrasound to reach its full potential in treating epilepsy,” said Foundation Chairman Neal Kassell, MD.  “This is the first in a planned series of studies in epilepsy that the Foundation is supporting.”

    In addition to the UVA study, the Foundation plans to support a clinical trial led by Neurosurgeon Vibhor Krishna, MD, at Ohio State University using focused ultrasound to ablate the anterior nucleus of the thalamus in patients with partial-onset epilepsy. 

    Neurosurgeon Tomokatsu Hori at Tokyo Women’s Medical University recently applied focused ultrasound to a patient with temporal lobe epilepsy (TLE) to assess feasibility of reaching this target. This is the first step that may ultimately lead to a clinical trial to treat TLE.
     
     
     
    Copyright © *|CURRENT_YEAR|* *|LIST:COMPANY|*, All rights reserved.
    *|IFNOT:ARCHIVE_PAGE|* *|LIST:DESCRIPTION|*

    Our mailing address is:
    *|HTML:LIST_ADDRESS_HTML|* *|END:IF|*

    unsubscribe from this list    update subscription preferences 

    forward to a friend *|IF:REWARDS|* *|HTML:REWARDS|* *|END:IF|*

    Continue reading >

  • Conference Report: International Parkinson and Movement Disorder Society

    The 20th International Congress of Parkinson's Disease and Movement Disorders was held June 19-23 in Berlin, Germany with more than 5,000 attendees. Seven focused ultrasound abstractswere presented, including the latest preliminary study data for Parkinson’s tremor and essential tremor.

    Continue reading >

  • JAMA Publishes Editorial, FDA Convenes Meeting on Prostate Patient Registry

    In an editorial published in the Journal of the American Medical Association (JAMA), Drs. Hu, Laviana, and Sedrakyan suggest that new technologies should be used cautiously until rigorous scientific evidence of safety and efficacy is available. This position is fully endorsed by the Focused Ultrasound Foundation.

    Continue reading >

  • FDA approves first MRI-guided focused ultrasound device to treat essential tremor

    On July 11, 2016, the US Food and Drug Administration (FDA) approved focused ultrasound to treat essential tremor. Read the FDA's release below.

     


    FDA logo 180The U.S. Food and Drug Administration today approved the first focused ultrasound device to treat essential tremor in patients who have not responded to medication. ExAblate Neuro uses magnetic resonance (MR) images taken during the procedure to deliver focused ultrasound to destroy brain tissue in a tiny area thought to be responsible for causing tremors.

    Continue reading >

  • Focused Ultrasound Foundation Featured as Leading Philanthropy By Virginia Business

    The Focused Ultrasound Foundation is featured on the cover of the annual Generous Virginians issue of Virginia Business magazine out this June and now available online.

    Continue reading >

  • Focused Ultrasound Recognized as a Top Emerging Technology with Potential to Revolutionize Neurologic Care

    Focused ultrasound has been recognized by Partners HealthCare as one of the “Disruptive Dozen” emerging technologies with the potential to revolutionize neurological and psychiatric care over the next decade.

    Continue reading >

  • Focused Ultrasound Used to Heat Brain Tumors

    After battling breast cancer for 12 years, Cynthia received devasting news; the cancer had spread to her brain. That's when Cynthia and her family turned to a clinical trial investigating the use of focused ultrasound.

    Continue reading >

  • In Memoriam: Floyd Dunn

    On January 24, we lost one of the giants of therapeutic ultrasound when Professor Floyd Dunn passed away at age 90.

    Continue reading >

  • Workshop Creates Roadmap for Brain Simulation

    Thirty leading engineers, physicists, and clinicians from 17 organizations convened at the Brain Workshop on Treatment Envelope & Simulation in Charlottesville February 2-3. They gathered to discuss ways to create accurate computer simulations to assess expanding the treatable area of the brain (treatment envelope), to facilitate patient selection, and to predict and prevent unwanted secondary effects like skull heating.

    Continue reading >

  • Focused Ultrasound Named Technology to Watch

    Medical Device and Diagnostic Industry (MD+DI) recently listed focused ultrasound as one of its top five technologies to watch in 2015.

    Continue reading >

  • Elekta’s Executive Director Shares Insight, Praises the Role of the Focused Ultrasound Foundation

    Tomas Puusepp, Executive Director of the Board of Elekta and its former CEO, recently visited the Foundation and shared his experience in providing an emerging technology (the Gamma Knife) to the patients who need it. His thoughts on taking risks, competition, and overcoming barriers provide many valuable insights that apply to focused ultrasound.

    When Puusepp joined Elekta in 1988, it was a $5 million company with a staff of 22—today it has $1.5 billion in revenue and 4,000 employees. With a background in electrical engineering and physics, he advanced through the management ranks within Elekta to serve as President and CEO from 2005 through April 2014.

    Continue reading >

  • FORTUNE Publishes Focused Ultrasound Double Feature

    FORTUNE has published two fantastic articles about the potential of focused ultrasound.  

    Continue reading >

  • Update from California Brain Tumor Patient

    “It started as a leap of faith and ultimately turned into a miracle.” That is how Cheryl Hanson describes the experience traveling from California to Switzerland in order for her husband, Dr. Peter Baginsky, to undergo focused ultrasound treatment of his aggressive glioblastoma brain cancer. As we reported in March, Peter was the first person to have a portion of his brain tumor thermally ablated through the intact skull using focused ultrasound.

    Continue reading >

  • Focal Prostate Cancer Study Begins at City of Hope

    A new InSightec study to determine feasibility and safety of using the ExAblate System to treat localized, low-risk prostate cancer has begun in California. Jeffrey Wong, MD, Professor and Chair of the Department of Radiation Oncology and Associate Director of the Prostate Cancer program at City of Hope in Duarte, California is the principle investigator at City of Hope. The study will begin enrolling at the Mayo Clinic in Rochester, Minnesota, and other locations. City of Hope is the first U.S. site to treat a patient enrolled in this study. 

    Patients who are interested in this study, should contact Maria Brooks at City of Hope (626) 256-4673 ext 64402, or Connie Sathre at Mayo Clinic (507) 538-0540, .

    Continue reading >

  • Focused Ultrasound Featured at Society for Thermal Medicine Meeting

    At the 31st Annual Meeting of the Society for Thermal Medicine (STM) on May 9th in Minneapolis, the Foundation’s Scientific Director, Jessica Foley, PhD, reviewed recent advances of focused ultrasound (FUS) therapy in oncology, the current global adoption and development landscape, and the Foundation’s strategy for advancing this field. A particular area of interest at the meeting was the use of hyperthermia – including FUS ablation – to induce an enhanced immune response for more effective treatment of cancer.

    Continue reading >

  • Nature Neuroscience: Focused Ultrasound Enhances the Brain’s Sensory Perception

    As reported in the current issue of Nature Neuroscience, scientists on Dr. William J. Tyler’s research team at Virginia Tech were interested in using focused ultrasound to noninvasively modify human brain function. They targeted sensory areas of the brain and were surprised by their findings: low-intensity focused ultrasound significantly improved function by decreasing impulses to the median nerve in the arm thereby enhancing the patients’ ability to discriminate between different kinds of stimulation. Secondly, they were impressed that the focused ultrasound could target smaller, more specific areas in the brain as compared to other neuromodulation technologies.

    Continue reading >

  • Focused Ultrasound for Parkinson's Disease Featured in Practical Neurology

    Focused ultrasound treatment for Parkinson's disease was featured as the cover story in the December issue of Practical Neurology.

    The article consisted of a Q&A with Dr. Binit B. Shah, MD, Assistant Professor, Neurology, Parkinson's Disease and Movement Disorders Division at University of Virginia.

    Continue reading >

  • Radiology Today Features MR Guided Focused Ultrasound

    Radiology Today magazine featured a balanced article detailing the uses of focused ultrasound to treat a wide variety of disorders such as uterine fibroids, bone mets pain, essential tremor, Parkinson's disease, and more.

    Continue reading >

  • Kona Medical’s Focused Ultrasound System Treats Hypertension

    Kona Medical’s two ongoing WAVE studies demonstrated the ability of focused ultrasound to noninvasively reduce blood pressure in patients with drug-resistant hypertension. Renal nerve ablation with their focused ultrasound—based Surround Sound™ Renal Denervation System produced clinically significant drops in both systolic and diastolic blood pressure. For the combined studies, 73% of patients experienced a clinically significant drop in systolic blood pressure of 10 mmHg or more at three months and 81% at six months with no device-related serious adverse events. As impressive as the drop in blood pressure, the WAVE II study also uses a dosing pattern that reduced therapy time from 13 minutes to 3 minutes.

    Continue reading >

  • Two Focused Ultrasound Companies Recognized for Innovation

    As a true testament to the potential of focused ultrasound to change medicine, TWO out of 15 companies selected by Fierce Medical for their top 15 innovators of the year are focused ultrasound companies: InSightec and Kona Medical.

    Continue reading >

  • Ultrasound: The Go-to Treatment for Functional Brain Disorders?

    An article in Dotmed daily news, an online site which follows medical devices and the industry, featured this story on the use of focused ultrasound to treat brain disorders like essential tremor, OCD, and Parkinson's disease: 

    Continue reading >

  • Special Report Issued on Therapeutic Ultrasound

    Good overview article about some of the many applications of therapuetic ultrasound from Dotmed.com Daily News, an online journal about medical devices and technology.

    Continue reading >

  • Focused Ultrasound Reduces Tremor, Improves Quality of Life for ET Patients Study Shows

    AANS PRESS RELEASE Embargoed until April 29, 2013, 2:30 p.m. CDTContact:John A. IwanskiDirector of Member and Public Outreach(847) 378-0517 |

    Subjects of Phase I Study of Transcranial MR-guided Focused Ultrasound Thalamotomy See Reduced Tremor,Improved Quality of Life

    NEW ORLEANS (April 29, 2013) — Research findings offered today during the 81st American Association ofNeurological Surgeons (AANS) Annual Scientific Meeting show that the use of transcranial MR-guided focused ultrasoundfor producing a thalamotomy can have significant positive effects on subjects suffering from essential tremor.

    Continue reading >

  • Medicare Establishes Billing Code and Payment for Treating Pain Palliation of Bone Metastases Using InSightec’s MR Guided Focused Ultrasound (MRgFUS) Therapy

    TIRAT CARMEL, Israel, Apr. 18, 2013 – InSightec Ltd. announced today that the US Centers for Medicare & Medicaid Services (CMS), a federal agency within the US Department of Health and Human Services (HHS), has created a new billing code for MR guided focused ultrasound treatment of pain palliation of metastatic bone lesions and has established a Medicare payment rate for hospital outpatient departments.

    Continue reading >

  • HistoSonics Technology Could Be a Game-changer for Treating Prostate Disease

    U.S. start-up HistoSonics, Inc. is preparing to launch clinical trials using its noninvasive pulsed ultrasound technology to treat benign prostatic hyperplasia (BPH), an age-related condition that, over time, affects nearly all men. Estimates indicate that 50% of men over 50 and 80% of men over 80 have BPH. More than two million Americans have the condition and about 400,000 are treated surgically for BPH each year.

    Continue reading >

  • Healthcare Trends Support Focused Ultrasound’s Emergence as Prostate Cancer Treatment

     

    Executives of EDAP and SonaCare Medical – two focused ultrasound device makers that are engaged in commercialization activities – say healthcare trends are creating a unique opportunity for their companies and for men with localized prostate cancer.

    Continue reading >

  • Ultrasound May Replace Brain Surgery to Treat Hand Tremors

    On Monday, March 25, 2013, Canadian TV (CTV) broadcast a follow-up report about Tony Lightfoot, a man who had been severely debilitated by essential tremor for more than a decade. He was the fourth patient treated in the Focused Ultrasound Foundation-funded Essential Tremor Pilot Study at Sunnybrook Health Sciences Centre in Toronto.

    Continue reading >

  • New Online Site Can Help FUS Community Speak Out Regarding Sequestration

    Update from Jessica L. Foley, PhD, Scientific Director, Focused Ultrasound Foundation

    FasterCures has launched Sequestration Station, an online destination for relevant and up-to-date news, resources, facts, and FAQs about how sequestration – or automatic government spending reductions - could impact medical research. These automatic spending cuts will take effect in January 2013 unless Congress acts soon.

    Continue reading >

  • Novel Therapy Uses Focused Ultrasound to Inhibit Liver Tumor Growth

    The Journal of Gene Medicinehas e-published ahead of print a preclinical study about a novel gene delivery method and a novel strategy for treating liver tumors. A team of Chinese researchers report succeeded in inhibiting liver tumor growth and improving survival time by combining high intensity focused ultrasound ablation with ultrasound-targeted microbubbles loaded with the herpes simplex virus thymidine kinase gene.

    Continue reading >

  • FDA Approves New Non-Invasive, Non-Ionizing Radiation Therapy to Treat Pain from Bone Metastases

    InSightec, Ltd. announced today that its ExAblate MRI-guided Focused Ultrasound system has received FDA approval to treat pain associated with bone metastasis. This is the second FDA-approved use of the ExAblate, which gained regulatory approval in 2004 for the treatment of symptomatic treat uterine fibroids.

    Continue reading >

  • New Metamaterial Device Focuses Sound Waves and May Eliminate Need for Transducers of Different Sizes

    A cover article in The Journal of Applied Physics describes how a team of researchers at Penn State Materials Research Institute designed and computationally tested a device constructed of a manmade metamaterial that can manipulate a variety of sound waves. Expected to benefit almost all current sonic and ultrasonic applications, the invention could lead to more accurate and efficient high intensity focused ultrasound therapies.

    Continue reading >

  • 2012 ISTU Conference Proceedings Will Be Available Online

    The International Society for Therapeutic Ultrasound has completed arrangements to have the proceedings of its 2012 meeting in Heidelberg, Germany published online in an open access format by the American Institute of Physics. The Society is inviting everyone who delivered oral and poster presentations at the meeting to submit an extended abstract of up to six pages in length using the ISTU 2012 AIP template.

    ISTU is building a website for registering and uploading papers, and will soon provide access information to 2012 presenters. The submission deadline is September 2, 2012.

    Continue reading >

  • Celsion, Oxford University Using Thermodox and HIFU in Metastatic Liver Cancer Trial

    US biotech Celsion, Inc. will design and conduct a clinical trial in partnership with Oxford University (UK) to evaluate the use of its heat-activated drug, Thermodox, and ultrasound-guided high intensity focused ultrasound in treating patients with metastatic liver cancer.  Patient treatments are expected to begin later this year. The study is supported by the National Institute for Health Research Oxford Biomedical Research Centre. It will be conducted as a multi-disciplinary collaboration between Celsion, the Oxford University Institute of Biomedical Engineering and the Oxford University Hospitals NHS Trust.

    Continue reading >

  • Blog Spotlights National Center for Image-Guided Therapy at Brigham & Women’s Hospital

    HealthHub, a blog from Brigham & Women’s Hospital, recently profiled the institution’s National Center for Image-Guided Therapy. The blog acknowledged the center’s Co-Principal Investigators Ferenc Jolesz, MD and Clare Tempany, MD for their pioneering work in MR-guided focused ultrasound. Also acknowledged was Nathan McDannold, PhD, leader of a research program that is studying focused ultrasound in treating brain tumors, chronic pain and tremors and in opening the blood-brain barrier to facilitate drug delivery. The center’s is also investigating focused ultrasound treatments for breast and bone tumors and cardiac arrhythmias. READ BLOG

    Continue reading >

  • A Year After Treatment, Billy Williams Still "Very Happy" With FUS

    Billy R. Williams is proud to be the first patient in the world to receive focused ultrasound treatment for essential tremor. A year after his procedure, which marked the beginning of the ground-breaking pilot clinical trial at the University of Virginia, he reports being "very, very happy" with treatment results. In a video interview, Williams and UVA neurological physical therapist Diane Huss, PhD, say that some tremor has returned but is being managed by a small and well-tolerated drug dose.

    Continue reading >

  • Breast System Project Leads to International Collaborations on MR Thermometry for Liver and Brain Indications

    As Dennis Parker, PhD and his colleagues at the University of Utah continue to refine and advance their new HIFU system for breast tumors, they have also joined forces with Swiss and French researchers to solve the technical problems of measuring temperature changes during focused ultrasound treatments.

    In designing their system, the Utah team has come up against significant technical challenges. For example, they had to determine how to measure temperature changes in fatty tissues, adjust for motion-related errors and cover larger volumes at acceptable spatial and temporal resolution. Their quest for solutions led to a collaboration with University of Geneva researchers who are addressing similar problems in developing a HIFU system for liver tumors. The Foundation supported this collaboration through a $100,000 Research Award for a project entitled, “Robust MR thermometry for MRgHIFU in breast and liver.” (Click here to read a previous newsletter report about that project.)

    Continue reading >

  • Boston Globe Features Focused Ultrasound for the Brain

    In its April 23, 2012 edition, the Boston Globe spotlighted the work being done at the University of Virginia and Brigham and Women's Hospital to advance focused ultrasound treatments for the brain. Click here to read the report, "Brain surgery that’s not invasive."

    Continue reading >

  • Asian Markets are Leading the Way – an Update on Worldwide Focused Ultrasound Adoption

    Executive Perspective: Falko Busse, PhD, Philips Healthcare 

    Asian markets are leading the adoption of focused ultrasound, reports Falko Busse, PhD, vice president and general manager of MR-HIFU for Philips Healthcare.

    Continue reading >

  • Next Five Years Will Be Crucial in MR-guided Focused Ultrasound Adoption

    Executive perspective: Interview with Jacques Coumans, PhD (GE Healthcare)

    MR-guided focused ultrasound has entered a crucial period in terms of adoption,says Jacques Coumans, PhD, general manager for premium and interventional MRI at GE Healthcare. The pressing challenge, he says, is to “cross the chasm to mainstream clinical use” by expanding the number of sites by tenfold.

    Noting that there are now about 150 MR-guided focused ultrasound sites worldwide, Coumans explains, “We often call this the academic bolus range.” He says that more than 1,000 sites will be needed to achieve successful adoption of the technology.

    Optimistic about the future, Coumans adds, “I would characterize the field of MR-guided focused ultrasound in the following way: in five years, we will all wake up stating that the overnight success of MR-guided focused ultrasound was 15 years in the making.”

    Although the technology was pioneered primarily at the Brigham and Women’s Hospital in Boston more than a decade ago, the adoption of MR-guided focused ultrasound is happening faster outside of the United States. Coumans believes this trend is due to fewer regulatory and reimbursement hurdles in other countries.

    “One of the big advantages of MR-guided focused ultrasound could be that the quality of care is significantly improved, but one of the hurdles that we see is the cost associated with it. Obviously, having an MR machine with a very expensive option called focused ultrasound increases the cost of a procedure. Certainly here in the west – in the United States, in particular – there are regulatory and reimbursement hurdles that are very significant and take a long time to sort out.”

    There are also practical issues to address as more focused ultrasound therapies are introduced: who does the procedure and who owns the patient? Coumans foresees focused ultrasound expanding beyond radiology. The most likely users are oncologists and interventionists, he says.

    Coumans has worked in the field of MRI since 1985 and has been following MR-guided focused ultrasound since its inception. GE supplies the MR scanner for InSightec’s ExAblate system, which has received CE-marking for treating uterine fibroids, adenomyosis and metastatic bone tumors. The system is also approved in the U.S. for the treatment of uterine fibroids.

    “I think MR-guided focused ultrasound is an intellectually incredibly appealing combination of two modalities,” Coumans asserts. “The fact that you can [use it to] non-invasively treat and non-invasively deposit [drugs] is something that was not thought of 20 years ago. Non-invasive or minimally invasive therapies are the thing of the future, and patient centricity and humanizing radiology really stand in the forefront of why MR-guided focused ultrasound has this appeal for patients as well as for physicians.”

    According to Coumans, “It’s not so much just the focus on focused ultrasound, it’s the focus on using MRI to guide therapy because of its extreme suitedness to get soft tissue contrast properly portrayed and to follow up treatments over time,” he explains.

    Commenting on growing competition in the focused ultrasound marketplace, Coumans calls it a positive development. Intellectual competition, clinical case studies, multimodality and multicenter trials contribute to growth. “Any industry benefits from competition,” he notes. “We welcome it.”  - Written by Ellen C., McKenna

    Related content:

    At RSNA 2011, Jack Coumans talks about the MR Patient Experience Suite –

    http://newsroom.gehealthcare.com/articles/from-the-show-floor-jacques-coumans/

     

    Continue reading >

  • Yoav Medan Interviewed in Discovery Channel Video Series About Focused Ultrasound

    Yoav Medan, Chief Systems Architect of InSightec and Visiting Associate Professor, Biomedical Engineering at the Technion Institute of Technology, was interviewed for the Discovery Channel's online video content channel called Curiosity.Com in a series of videos about focused ultrasound.

    http://dsc.discovery.com/videos/curiosity-y-medan-what-excites-you-the-most-about-focused-ultrasound.html

     

    Continue reading >

  • Acublate: New Focused Ultrasound Company Formed

    Cancer Research Technology, the commercial arm of Cancer Research UK has spun off a private comapny called 'Acublate Limited' which will be developing a HIFU device used to treat various types of solid tumors.  Initially, the Acublate device will treat patients with bowel cancer that has spread to the liver.

    Dr Keith Blundy, CRT's CEO, said: "We're delighted to be able to take the research into this exciting technology that Cancer Research UK helped fund onto the next stage. The HIFU technology currently approved for clinical use in the UK specifically targets prostate cancer but we hope the Acublate device will be able to treat most solid tumour types."

    Read the press release here:

    http://www.cancertechnology.com/news/single/acublate/

     

    Continue reading >

  • TIME Magazine Features Focused Ultrasound as One of This Year's 50 Best Inventions

    The visibility of focused ultrasound is skyrocketing. TIME Magazine has named it one of the 50 most inspired ideas, innovations and revolutions of 2011. In its coverage, TIME heralds MR-imaging and focused ultrasound "remarkable in their own right"and observes that "something life-changing" emerges when the two are combined.

    Continue reading >

  • Facility Dedicated to Leading-edge Personalized Medicine Offers MR-guided focused Ultrasound

    "Visiting the center was like taking a journey into the future of healthcare. Its an amazing facility, organized around the concept of personalized medicine. The therapeutic goal is to create a positive and memorable experience for the patient," Huff-Simonin says.

    Opened in October 2010, the center was created by Kwang Yul Cha, MD, the founder and head of CHA Health Systems. CHA currently operates a global network of healthcare facilities that includes Hollywood Presbyterian Medical Center in Los Angeles, 12 general hospitals in Korea and two fertility treatment and anti-aging research centers in the US and Korea.

    Continue reading >

  • Baltimore Sun Article Asserts that Celsion’s Move to NJ is Driven by Lack of Talent in MD

    Celsion Corporation recently announced it is moving its headquarters from Columbia, MD to Princeton, NJ. An article published in yesterday’s Baltimore Sun asserts that the move is prompted by the lack of a labor pool in Maryland with experience in marketing, selling and distributing pharmaceuticals.

    In addition to sponsoring clinical trials that are assessing its heat-sensitive drug, Thermodox, as a treatment for liver and breast cancer, Celsion is working in partnership with Philips Healthcare to develop a new focal drug delivery treatment for metastatic bone cancer. The method combines  ThermoDox with Philips’ MR-guided focused ultrasound technology.

    Continue reading >

  • MR-guided Focused Ultrasound Spotlighted on the CBS Evening News

    A story pitched and facilitated by the Focused Ultrasound Surgery Foundation was broadcast on the CBS Evening News on June 12, 2011.

    Acknowledging that focused ultrasound could be one of the biggest medical advances since the scalpel, the report included interviews with uterine fibroid patient Stephanie Small and University of Virginia radiologist Alan Matsumoto, MD.

    Continue reading >

  • Novel Treatment for Deadly Brain Tumors Combines Nanoparticles, Microbubbles and Focused Ultrasound

    Richard J. Price, Ph.D. is investigating a novel combination of nanoparticles, microbubbles and focused ultrasound – a combination that he believes could effectively treat and possibly cure diseases of the central nervous system, including brain tumors, dementia and Parkinson’s disease.

    Continue reading >

  • Philips Sonalleve Receives CE Mark for MR-guided Focused Ultrasound Ablation of Metastatic Bone Cancer

    During last month's meeting of the European Congress of Radiology in Vienna, Philips Healthcare announced that its Sonalleve MR-HIFU system has received CE Marking for palliative care of patients with bone metastases. Equivalent to FDA approval in the U.S., CE Marking is recognized by countries in the European Economic Area and signifies that a product complies with the essential requirements of relevant health, safety and environmental protection legislation.

    The company acknowledged that it intends to seek similar approval in the U.S.

    Philips has been marketing the Sonalleve for uterine fibroid treatment since December 2009 and has installed 22 systems worldwide. The Sonalleve system uses ultrasound energy to ablate metastatic tissue and sensitive nerves around the bone, alleviating the significant pain experienced by advanced cancer patients. The system's MR imaging provides 3D planning and temperature monitoring.

    Continue reading >

  • Celsion, Philips Plan U.S. Clinical Trial of Thermodox for Bone Mets

    While most focal drug delivery research is still in the preclinical stage, the field's frontrunner, Celsion Corporation, has requested FDA permission to launch U.S. clinical trials of its investigational liposome-encapsulated drug, ThermoDox. Conducted in partnership with Philips Healthcare, those studies will investigate the use of ThermoDox in focused ultrasound-mediated drug delivery treatments for patients with metastatic bone cancer. Read more.

    Continue reading >

  • Essential Tremor Clinical Trials Are Off to a Successful Start

    A promising new, noninvasive treatment for patients with essential tremor is making headlines this week. As announced yesterday in a Focused Ultrasound Surgery Foundation press release, a clinical trial at the University of Virginia has successfully used MR-guided focused ultrasound to treat its first patient - a man who had been unable to use his dominant right hand for more than a decade due to essential tremor. The focused ultrasound procedure completely stopped the man's tremor, and doctors are hopeful that it will not return. The treatment involved no anesthesia, incisions or ionizing radiation and targeted the thalamus, an area deep within the brain that has been associated with movement disorders.

    The Focused Ultrasound Surgery Foundation is funding the UVA trial, which is being conducted under an FDA-aproved protocol and could treat as many as 15 patients. The Foundation is also funding a parallel clinical trial at Sunnybrook Health Sciences Centre in Toronto, which is scheduled to begin later in 2011 under a Health Canada-approved protocol. Click hereto read the Foundation's press release.

    Continue reading >

  • Dr. Elias talks about the first treatment of ET with Focused Ultrasound

    Continue reading >

  • New Transurethral Ultrasound Device Could Be a "Killer App" for Treating Men With Benign Prostatic Hyperplasia (BPH)

    Graham Sommer, M.D., professor of radiology at Stanford University Medical Center, is opening up a new frontier in men's health for MR-guided focused ultrasound treatments. He and his colleagues at Stanford and the University of California, San Francisco have developed a device that uses this innovative, noninvasive technology to treat benign prostatic hyperplasia, or BPH. Click here to view video interview and read full report.

    Continue reading >

  • More Sites and Patients Join Clinical Trial Assessing New MR-guided FUS System for Prostate Cancer

    Vendor Update: InSightec, Ltd., Israel 

    InSightec reports that two new sites have joined its Phase 1 clinical trial assessing the ExAblate Prostate System and 14 patients with low-risk prostate cancer have now received treatment.

    The newly added sites are the University of Rome in La Sapienza, Italy; and Jaslok Hospital in Mumbai, India. The other participating sites are the N.N. Petrov Research Institute of Oncology in Saint Petersburg, Russia and the National Cancer Centre at the Singapore General Hospital, Singapore.

    Continue reading >

  • Two U.S. Sites will Conduct Clinical Trial of Profound Medical’s New MR-guided Thermal Ultrasound Treatment for Prostate Cancer

    Vendor update: Profound Medical, Inc., Canada

    As many as 30 patients with early stage prostate cancer could be treated with a new, minimally-invasive device in a clinical trial expected to begin at two U.S. hospitals later this year, says Paul Chipperton, CEO of Profound Medical, Inc. (PMI). The Toronto-based venture is commercializing intellectual property and technology licensed from Sunnybrook Health Sciences Centre.

    Continue reading >

  • MR-guided Focused Ultrasound System Designed Specifically for Breast Tumor Ablation

    The January 24 issue of Aunt Minnie.com Ultrasound Insideroffers a link to a story about a MR-guided focused ultrasound system designed specifically for breast tumor ablation. Under development at the University of Utah School of Medicine in Salt Lake City, the system was the topic of a presentation given by Allison Payne, PhD, at the FUS Foundation’s 2nd International Symposium on MR-guided Focused Ultrasound in October 2010. Click hereto read the report, which was published by MedicalPhysicsWeb.com.

     

     

     

     

    Continue reading >

  • 4th Therapeutic Ultrasound School Set for March 14-18 in France

    The FUS Foundation is one of the sponsors of the 4th Therapeutic Ultrasound School being held in Les Houches, France. Successor to the hugely successful schools in Oxford and Corsica, the program will explore the rapidly emerging field of therapeutic ultrasound. Topics will range from an introduction to the physics and biophysics necessary for understanding these techniques to clinical applications. Each topic will be covered by an invited speaker who is a world authority in the field.

    For more information, visit the information page or download the flyer. Spaces are limited, so register early!

    Continue reading >

  • Leading Edge Facilities at Sunnybrook Research Institute (SRI) in Toronto are Amazing

    Last month, John Snell, Ph.D. (Technical Director of the FUS Foundation Brain Program) and I visited Sunnybrook Research Institute (SRI) in Toronto, ON. We had the pleasure of touring the incredible facilities there.

    Kullervo Hynynen, Ph.D., Director of the Imaging Centre, showed us around the research space that houses the labs of nearly 20 faculty members doing imaging research. This space includes dedicated clinical, pre-clinical and laboratory areas for research in focused ultrasound.  In addition, the Centre has manufacturing capabilities for transducer design and development. Thus, its staff can build solutions in-house and test them through the full translational process from design through pre-clinical and clinical testing. 

    Continue reading >

  • MR-guided FUS Could Have "Huge Impact" on Pancreatic Cancer Drug Delivery

    The hardest part of his job, says Joo Ha Hwang, M.D., Ph.D., is informing patients that they have pancreatic cancer.

    Hwang, a leading researcher in focused ultrasound and gastroenterologist at the University of Washington in Seattle, is troubled by the lack of effective treatments for this deadly disease. "For decades, we've been treating pancreatic cancer and coming up with one new drug regimen after another. Yet, nothing has made a dent in improving patient survival," he notes.

    Preclinical studies using MR-guided focused ultrasound for targeted drug delivery have achieved promising results, and Hwang believes clinical trials could begin within the next two years. "The potential impact of focused ultrasound could be huge," he says. "It could completely change the paradigm for treating patients with pancreatic cancer."

    Read more and view video>

    Continue reading >

  • Chen Reports MR-guided Focused Ultrasound Has Potential to Boost Efficacy of Prostate Cancer Drug

    On June 14, 2011, GE Healthcare Korea and InSightec, Ltd. co-hosted a conference to recognize two important developments in the focused ultrasound community.

    First was the attainment of the 500-patient mark by the focused ultrasound team at CHA Bundang Medical Center in Seoul. Under the leadership of Sang-Wook Yoon, MD, the team has been treating uterine fibroid patients for five years. CHA’s one-year follow up data shows that 95% of patients have experienced improvement and that 18 have either become pregnant or given birth.

    The second development acknowledged at the event is the purchase of ExAblate brain and body systems by Yonsei University Medical Center. Jin Woo Chang, MD will use the new brain system to conduct the world’s first clinical trial in which patients with obsessive compulsive disorder (OCD) will receive MR-guided focused ultrasound therapy. Yonsei researchers are also planning clinical trials involving patients with metastatic bone tumors, low-risk and intermediate risk prostate cancers, essential tremor, and brain cancer.

    Continue reading >

  • MR-guided FUS Shows Exciting Promise as Noninvasive Treatment for Back Pain

    As a noninvasive therapy for the extreme back pain of facet joint osteoarthritis, MR-guided focused ultrasound shows considerable promise, reports Even Weeks, M.D., a FUS Foundation funded fellow at St. Mary’s Hospital in London.

    Weeks and his colleagues are conducting a prospective, non-randomized clinical trial to evaluate the safety and efficacy of Insightec’s ExAblate system as a therapeutic technique for facet joint pain. Their goal is to enroll 20 to 25 patients and to follow them for a year to assess adverse effects, pain levels and functional outcome measures.

    Continue reading >

  • A Small (Funding-Wise) Focus on CER for Fibroids

    Discussions about Comparative Effectiveness Research (CER) were not commonplace conversation just over a year ago, but as the Health Care Reform initiative has progressed, it seems that nearly every single day we hear something about CER. Just last week Medical Devices Today published a piece about the amount of NIH Comparative Effectiveness Research funding dollars committed solely to medical-device-focused CER in 2009, and the number was significant at $40 Million. While some of these monies were directed to the establishment of CER centers at different universities, the majority involved short-term (2 year) studies in CER with funding totals for each project approximately $500,000. These short-term projects were funded through the American Recovery and Reinvestment Act of 2009 as part of the economic stimulus package.

    Continue reading >

  • ISTU Report

    The 9th Annual International Society of Therapeutic Ultrasound (ISTU) met recently in Aix en Provence, France and featured 128 speakers, dozens of technical posters, and brought together hundreds of experts in the field of focused ultrasound research. The meeting, sponsored in part by the FUS Foundation, is the premier yearly conference highlighting the engineering and technical work done to allow focused ultrasound to treat a myriad of medical conditions. Particularly exciting was the number of young and talented investigators that are leading the wave of new advances and applications. Also exciting was the large presence of equipment manufacturers showcasing their latest advancements including Philips, InSightec, Siemens, Haifu, Supersonic Imagine, and Profound Medical.

    Featured prominently at the meeting was the more established use of focused ultrasound in heating targeted areas of the body to destroy diseased tissue and the conference included the latest advances in using the technology to treat uterine fibroids, prostate cancer, breast cancer, brain tumors, and other diseases. One of the tumor types receiving particular attention this conference were liver tumors which require special techniques to pass the ultrasound beams through the rib cage and visualize and track the liver while in motion due to the patient’s respiration. In addition to the use of focused ultrasound to ablate diseased tissue non-invasively, there was more emphasis than ever on the non-thermal applications of focused ultrasound in areas such as targeted drug delivery and the disruption of clots found in stroke patients.

    Some highlights of the ISTU meeting observed by members of the Foundation staff include the following:

    Continue reading >

  • Landmark Progress in Noninvasive Treatment of Brain Disorders


    Ten-patient
    functional neurosurgery feasibility study shows potential for treating brain disorders with MR-guided focused ultrasound

    Eben Alexander III, M.D., and Rolf Taylor

    A groundbreaking new study has paved the way for clinical studies on the noninvasive treatment of a broad spectrum of brain disorders including Parkinson's disease, epilepsy, stroke, and brain tumors.

    A team at the University of Zürich, in Switzerland, has completed a pilot study using MR-guided focused ultrasound to treat 10 patients with neuropathic pain. The origin of pain in these patients included post-amputation phantom limb syndrome, nerve injury, stroke, trigeminal neuralgia, and post-herpetic neuralgia from shingles.  The findings will be published in a forthcoming issue of Annals of Neurology.

    The study was partially funded by the Focused Ultrasound Surgery Foundation, which funds translational and clinical research into new therapeutic applications of MR-guided focused ultrasound (MRgFUS).

    The preliminary results in these patients are comparable to those obtained with conventional therapy – radiofrequency ablation – an invasive procedure that involves making an incision in the scalp, drilling a hole in the skull, inserting an electrode through normal brain tissue into the thalamus, and using radiofrequency electromagnetic waves to create the lesion.

    Functional neurosurgery involves alteration of the brain’s circuitry to treat various neurological conditions such as pain, movement, and behavioral disorders. It is a growing discipline that has developed over more than 60 years.  In general, treatment involves creating  lesions (destruction) in a neural circuit using radiofrequency ablation, or placing an electronic deep brain stimulator (DBS) to modulate the activity of a circuit.  Ablation has the advantage of treating the patient with a single procedure; however, it involves the risk of long-term neurological complications if the location of the lesion is suboptimal.

    Use of DBS has the advantage of reversibility in the event of improper location, but is far more expensive in terms of monetary cost and the time spent by specialists programming and maintaining the stimulator and its power supply. In addition, both ablative lesions (commonly performed by inserting a radiofrequency electrode) and DBS involve electrode passage through the brain itself, with a significant risk of hemorrhage or infection. The latter is especially problematic in DBS placement for patients with Parkinson’s Disease, whose state of health and poor self-care result in four to seven times the risk of infection, compared to general neurosurgical patients.

    Stereotactic radiosurgery (using the Gamma Knife or Linear Accelerator) has demonstrated a somewhat limited applicability as a noninvasive method in certain functional neurosurgical disorders, especially trigeminal neuralgia (a common type of facial pain). However, its use of high levels of ionizing radiation may lead to significant complications.

    Focused ultrasound is the first truly noninvasive treatment approach to emerge as an alternative to surgery and radiation. By focusing thousands of ultrasound beams on a single point, the medical team can achieve the same therapeutic effect as radio frequency ablation and radiosurgery, but without the risks and complications associated with traditional surgery or ionizing radiation.

    “This study showed that we can perform successful operations in the depths of the brain without opening the cranium or physically penetrating the brain with medical tools, something that appeared to be unimaginable only a few years ago,” says Daniel Jeanmonod M.D., a neurosurgeon at the University of Zürich and the study’s co-principal investigator.

    “By eliminating any physical penetration into the brain, we hope to duplicate the therapeutic effects of invasive deep brain ablation without the side effects, and for a wider group of patients. The research funding from the Focused Ultrasound Surgery Foundation allowed us to conduct the study rapidly and with scientific rigor,” adds Dr Jeanmonod. “We are an academic institution and this type of award is essential to our research process.”

    According to Neal Kassell, M.D., a neurosurgeon at the University of Virginia and chairman of the Focused Ultrasound Surgery Foundation, the key advantage of focused ultrasound is that it is noninvasive. This, in principle, makes it safer than conventional surgery by avoiding the associated risks of infection, hemorrhage, and damage to the brain.

    “This research demonstrates that MR-guided focused ultrasound can be used noninvasively to produce small thermal ablations with extreme precision and accuracy deep in the brain,” explains Dr Kassell. “This lays the foundation for revolutionizing the treatment of a variety of brain disorders that traditionally required surgery, including Parkinson's disease and essential tremor, epilepsy, brain tumors, and stroke.”

    “We are pleased to have been able to provide funding for this groundbreaking research,” adds Eben Alexander, M.D., director of the Brain Development Program at the Focused Ultrasound Surgery Foundation. “Dr. Jeanmonod’s work may help open the door to enable the noninvasive treatment of some of these most prevalent brain disorders.”

    Other research sites are expected to initiate clinical studies on the use of MR-guided focused ultrasound for treating brain disorders within the next year.

    {sharethis}

    Continue reading >

  • 10th Neurosurgery Patient Treated at Zurich Hospital with Focused Ultrasound

    The University Children’s Hospital in Zurich, Switzerland recently celebrated treating its tenth neurosurgery patient with focused ultrasound. The patient had suffered for almost ten years from neuropathic pain – pain that originated when a benign brain tumor damaged nerve fibers in his brain which led to extreme pain and cramping in his right arm.

    Continue reading >

  • CBN Features Story on Focused Ultrasound and the Foundation

    The Christian Broadcasting Network (CBN) recently ran a feature on its telecast and web site about focused ultrasound surgery and the role of the FUS Foundation in accelerating the development and adoption of FUS technology.

    Entitled "The Sonic Miracle," the piece highlights the exciting current uses of the technology and some of the revolutionary possibilities the future holds.
    Featured in the article are use of the InSightec ExAblate system by Dr. Suzanne LeBlange of University MRI in Boca Raton, the experiences of two patients being treated for uterine fibroids, and commentaries by Dr. Neal Kassell and Dr. Joy Polefrone of the FUS Foundation and Pat Robertson of CBN.

    This feature represents significant media exposure for focused ultrasound. The CBN is broadcast in 95 percent of US viewing markets and is seen daily by about 1 million viewers. In addition, 650,000 people view CBN's web site each month. The response of patients and clinicians to this feature has been overwhelming with scores calling and emailing for more information. The web site article and accompanying video can be seen on the CBN web site here

    Continue reading >

  • See It Early, Treat It Early. MR Makes Waves for Prostate Cancer in Hawaii

    Prostate cancer: When will we have a reliable prostate cancer screening system for men, and when we do, how will we treat those many cases of early-stage prostate cancer that are detected? 

    Are we inching closer to a “ManoGram”? Rolf Taylor contemplates the current landscape – and the potential for increased research funding in the near future.

    1 in 6 men will face prostate cancer in their lifetime, and each year it will kill 28,000 men in the U.S. alone. But unlike breast cancer, for which outcomes have improved dramatically as a result of near universal mammograms and advances in treatment options, prostate cancer remains stubbornly under diagnosed. Patients with rising PSA levels who show signs of malignancy don’t want to risk doing nothing, but can’t be sure that they definitely need treatment. And surgery carries major risks including erectile dysfunction and incontinence. Many patients need a blood transfusion during surgery. 

    Continue reading >